A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
John F R RobertsonAbigail EvansStephan HenschenCliona Clare KirwanAli JahanLaura M KennyJ Michael DixonPeter SchmidAshutosh KothariOmar MohamedPeter Andreas FaschingKwok Leung CheungRachel WuerstleinDanielle CarrollTeresa KlinowskaJustin P O LindemannAlexander MacDonaldRichard MatherRhiannon MaudsleyMichele MoschettaMyria NikolaouMartine P RoudierTinnu SarvothamGaia SchiavonDiansong ZhouNadia HarbeckPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This was the first presurgical study to demonstrate that an oral SERD affects its key biological targets. However, AZD9496 was not superior to fulvestrant at the dose tested.